ReShape Lifesciences Inc
NASDAQ:RSLS
Balance Sheet
Balance Sheet Decomposition
ReShape Lifesciences Inc
ReShape Lifesciences Inc
Balance Sheet
ReShape Lifesciences Inc
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
7
|
3
|
73
|
21
|
21
|
14
|
4
|
23
|
4
|
4
|
1
|
|
| Cash Equivalents |
7
|
3
|
73
|
21
|
21
|
14
|
4
|
23
|
4
|
4
|
1
|
|
| Short-Term Investments |
12
|
9
|
3
|
23
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
1
|
1
|
4
|
1
|
0
|
3
|
3
|
2
|
2
|
1
|
|
| Accounts Receivables |
0
|
1
|
1
|
4
|
1
|
0
|
0
|
3
|
2
|
2
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
1
|
1
|
2
|
2
|
0
|
3
|
4
|
4
|
2
|
|
| Other Current Assets |
0
|
0
|
1
|
2
|
2
|
2
|
1
|
1
|
0
|
0
|
0
|
|
| Total Current Assets |
20
|
14
|
78
|
52
|
29
|
18
|
8
|
30
|
10
|
10
|
5
|
|
| PP&E Net |
0
|
0
|
1
|
1
|
2
|
2
|
1
|
2
|
1
|
0
|
0
|
|
| PP&E Gross |
0
|
0
|
1
|
1
|
2
|
2
|
1
|
2
|
1
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
2
|
2
|
3
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
21
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Total Assets |
21
N/A
|
14
-31%
|
79
+454%
|
53
-33%
|
30
-43%
|
20
-33%
|
11
-48%
|
53
+395%
|
11
-79%
|
11
-4%
|
5
-55%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
3
|
2
|
2
|
2
|
|
| Accrued Liabilities |
1
|
3
|
4
|
6
|
6
|
3
|
4
|
3
|
4
|
1
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
1
|
0
|
2
|
10
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Other Current Liabilities |
0
|
2
|
0
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Total Current Liabilities |
1
|
6
|
5
|
10
|
17
|
4
|
5
|
8
|
7
|
4
|
5
|
|
| Long-Term Debt |
5
|
9
|
10
|
8
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
6
N/A
|
15
+155%
|
14
-1%
|
18
+24%
|
17
-4%
|
5
-74%
|
6
+31%
|
8
+38%
|
7
-9%
|
4
-47%
|
5
+26%
|
|
| Equity | ||||||||||||
| Common Stock |
55
|
55
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
41
|
56
|
77
|
111
|
149
|
172
|
185
|
578
|
624
|
636
|
643
|
|
| Additional Paid In Capital |
1
|
1
|
141
|
146
|
162
|
188
|
189
|
622
|
628
|
642
|
643
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
15
N/A
|
0
N/A
|
64
N/A
|
35
-45%
|
13
-63%
|
16
+21%
|
5
-71%
|
44
+849%
|
4
-92%
|
7
+82%
|
0
N/A
|
|
| Total Liabilities & Equity |
21
N/A
|
14
-31%
|
79
+454%
|
53
-33%
|
30
-43%
|
20
-33%
|
11
-48%
|
53
+395%
|
11
-79%
|
11
-4%
|
5
-55%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|